C

Cara Therapeutics
D

CARA

0.41470
USD
-0.01
(-1.87%)
Market Open
Volume
2,402
EPS
-1
Div Yield
-
P/E
-0
Market Cap
22,748,582
OverviewSignalsIdeasNews
Related Instruments
    A
    ACB
    -0.07000
    (-1.64%)
    4.20000 USD
    C
    CGC
    -0.03500
    (-1.24%)
    2.78500 USD
    C
    CRBP
    -0.030
    (-0.23%)
    12.930 USD
    C
    CRON
    0.02500
    (1.28%)
    1.98500 USD
    H
    HEXO
    -0.03000
    (-2.36%)
    1.23000 USD
    T
    TLRY
    0.08000
    (6.43%)
    1.32500 USD
    Z
    ZYNE
    0
    (0%)
    0.000000 USD
    More
News

Title: Cara Therapeutics

Sector: Healthcare
Industry: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.